The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) (FOrMe)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03949972|
Recruitment Status : Recruiting
First Posted : May 14, 2019
Last Update Posted : August 22, 2019
|Condition or disease||Intervention/treatment|
|Glomerulosclerosis, Focal Segmental Minimal Change Disease Idiopathic Nephrotic Syndrome||Other: Biosampling|
Idiopathic Nephrotic Syndrome is characterized by proteinuria, volume retention, hyperlipidemia, hypoalbuminemia. As Minimal Change Disease (MCD) represents by far the most prevalent underlying diagnosis in children older than 1 year, a kidney biopsy is usually deferred in these cases. In adolescence and adults, a kidney biopsy is crucial for the diagnosis because MCD and FSGS account for only 10-15 and 12-35 percent of all cases of nephrotic syndrome respectively. Pathomechanisms as well as optimal treatment remain elusive as systematic trials are scarce and hampered by low incidence and heterogenicity of the clinical presentation. To bridge this informational gap, the investigators identified the need for a German registry of pediatric and adult patients with idiopathic nephrotic syndrome (in children) and biopsy-proven MCD/FSGS (in adults).
The registry will record clinical data of participants regarding basic demographics, initial presentation, hereditary traits, disease course and treatment modalities as well as quality of life, concomitant diseases, and comedication. During the initial visit and to a lesser intent on follow-up visits, biomaterials (blood, urine, DNA, feces, tissue) will be collected and stored in a state-of-the art biobank. This material will be available to collaborators to support research on idiopathic nephrotic syndrome and MCD/FSGS. By the time of completion, the registry will provide data on clinical courses and outcome of approximately 500 patients that can easily be correlated with biomaterials giving insight into risk factors, prognostic parameters, and association with comorbidities.
Tissue sections of all patients that undergo kidney biopsy (all adult and some pediatric patients) will be digitalized, annotated, and analyzed by a panel of nephropathologists. Histopathologic features will be individually assessed and scored according to a set of descriptors that was developed and is used by the American NEPTUNE (Nephrotic Syndrome Study Network).
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||500 participants|
|Target Follow-Up Duration:||15 Years|
|Official Title:||The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)|
|Actual Study Start Date :||April 1, 2018|
|Estimated Primary Completion Date :||March 31, 2028|
|Estimated Study Completion Date :||March 31, 2033|
A - Pediatric Cohort
Pediatric patients until 18 years of age presenting with or diagnosed with idiopathic nephrotic syndrome or a biopsy-proven diagnosis of MCD or FSGS.
Biosampling at initial visit and follow-up visits
B -Adult Cohort
Adult patients 18 years and above with a biopsy-proven diagnosis of primary or secondary FSGS or MCD.
Biosampling at initial visit and follow-up visits
- Average Annual Change in estimated glomerular filtration rate (eGFR) [ Time Frame: 5-15 years ]Outcome measure: eGFR loss in ml/min/year. Higher values are considered worse outcome.
- Incidence of End-stage Renal Disease (ESRD) [ Time Frame: 5-15 years ]Documented initiation of chronic renal replacement therapy regardless of type.
- Incidence of Death [ Time Frame: 5-15 years ]Documented patient death due to any cause
- Incidence of Kidney Transplantation [ Time Frame: 5-15 years ]Documented kidney transplantation regardless of type (living donor, cadaveric donor)
- Changes in Quality of Life (adults patients) [ Time Frame: 5-15 years ]
Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals using the SF-36 questionnaire.
For reference see https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html The SF-36 questionnaire measures eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. Lowest and highest possible scores are 0 and 100. Scores represent the percentage of total possible score achieved.
Original publication: Ware, J.E., Jr., & Sherbourne, C.D. "The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection,". Medical Care, 30:473-483, 1992.
- Changes in Quality of Life (pediatric patients) [ Time Frame: 5-15 years ]
Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals using the PedsQL questionnaire.
For reference see https://www.pedsql.org/score.html The PedSQL questionnaire measures four health concepts: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To create Scale Scores, the mean is computed as the sum of the items over the number of items answered (this accounts for missing data). To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03949972
|Contact: Paul T Brinkkoetter, MDemail@example.com|
|Contact: Linus A Voelker, MDfirstname.lastname@example.org|
|University Hospital of Cologne||Recruiting|
|Cologne, NRW, Germany, 50937|
|Contact: paul brinkkoetter, MD +49-221 478-4480 email@example.com|
|Contact: Lutz Weber, MD +49 221 478-4319 firstname.lastname@example.org|
|Sub-Investigator: Linus Völker, MD|
|Sub-Investigator: Paul Brinkkötter, MD|
|Sub-Investigator: Rasmus Ehren, MD|
|Sub-Investigator: Franziska Grundmann, MD|
|Sub-Investigator: Thomas Benzing, MD|
|Study Director:||Paul T Brinkkoetter, MD||University Hospital of Cologne, Cologne, Germany|